Logo

Sciex CESI 8000 Plus

Nov 10, 2015

Sciex has launched the CESI 8000 Plus, a next-generation CESI-MS platform. The new system enables multiple experiments to be generated from as little as 5 mL of starting material. Combining this capability with the multi-segment injection technology, users can process 10 experiments in the time it would normally take to process one, with less than 1 L of material consumed, Sciex said. The system is ideal for experiments with limited samples, including microdialysates, needle biopsies, FFPE archives, and rare circulating tumor cells; or where samples are highly toxic. In addition, the innovation of neutral capillary surfaces further reduces system flow to less than 10 nanoliters/min, the company said. The platform also delivers higher-resolution separations, improved ionization efficiency, and reduced ion suppression. Optional laser-induced fluorescence, diode-array, and selectable wavelength UV detector modules are available, enabling off-line method development.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.